Pi3K-mTOR Signaling and AMOG Expression in Epilepsy-associated Glioneuronal Tumors

Overview

Journal Brain Pathol

Date 2009 Apr 18

PMID 19371356

Citations 31

Authors

Karin Boer

Dirk Troost

Wendy Timmermans

Peter C van Rijen

Wim G M Spliet

Eleonora Aronica

Affiliations

Soon will be listed here.

Abstract

Gangliogliomas (GGs) and dysembryoplastic neuroepithelial tumors (DNTs) represent the most frequent type of neoplasms in pediatric medically intractable epilepsy. Several data suggest a pathogenetic relationship between GGs and other glioneuronal malformations of cortical development (MCDs), including activation of the Pi3K-mTOR signaling pathway. To further reveal these pathogenetic similarities, we investigated immunocytochemically the expression of phosphorylated (p)-PDK1, p-AKT, p-mTOR, p-4E-BP1, p-eIF4G, p-p70S6K and p-S6, the effector proteins ERM (ezrin/radixin/moesin) and the pathway regulator AMOG (adhesion molecule on glia) in both GGs and DNTs. Components of the Pi3K-mTOR signaling pathway were observed in a higher percentage of neuronal cells in GGs compared with control cortex. In DNTs, the expression of these components was low and comparable with the expression in control samples. Strong immunoreactivity for ERM was observed in GGs, but not in DNTs. Additionally, AMOG was strongly expressed within GGs (but not in DNTs) in CD34-positive precursor cells. These findings support the previously suggested pathogenic relationship between GG and MCDs concerning activation of the Pi3K-mTOR signaling pathway and suggest a different pathogenetic origin for DNTs. The strong expression of AMOG within the precursor cells of GG may represent an additional marker for the diagnostic evaluation of these glioneuronal lesions.

Citing Articles

WONOEP appraisal: The role of glial cells in focal malformations associated with early onset epilepsies.

Cases-Cunillera S, Quatraccioni A, Rossini L, Ruffolo G, Ono T, Baulac S Epilepsia. 2024; 65(12):3457-3468.

PMID: 39401070 PMC: 11647439. DOI: 10.1111/epi.18126.

Glioma genetic profiles associated with electrophysiologic hyperexcitability.

Tobochnik S, Dorotan M, Ghosh H, Lapinskas E, Vogelzang J, Reardon D medRxiv. 2023; .

PMID: 36865325 PMC: 9980233. DOI: 10.1101/2023.02.22.23285841.

13-Acetoxysarcocrassolide induces apoptosis in human hepatocellular carcinoma cells through mitochondrial dysfunction and suppression of the PI3K/AKT/mTOR/p70S6K signalling pathway.

Hsu C, Lin J, Su J, Liu C Pharm Biol. 2022; 60(1):2276-2285.

PMID: 36416062 PMC: 9704080. DOI: 10.1080/13880209.2022.2145489.

Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.

Cases-Cunillera S, van Loo K, Pitsch J, Quatraccioni A, Sivalingam S, Salomoni P Neuro Oncol. 2021; 24(5):741-754.

PMID: 34865163 PMC: 9071348. DOI: 10.1093/neuonc/noab268.

Lentivirus vector‑mediated genetic manipulation of oncogenic pathways induces tumor formation in rabbit brain.

Ahmad F, Hyvarinen A, Pirinen A, Olsson V, Rummukainen J, Immonen A Mol Med Rep. 2021; 23(6).

PMID: 33846766 PMC: 8047887. DOI: 10.3892/mmr.2021.12061.

References

Ljungberg M, Bhattacharjee M, Lu Y, Armstrong D, Yoshor D, Swann J . Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol. 2006; 60(4):420-9. DOI: 10.1002/ana.20949. View

Bellacosa A, Kumar C, Di Cristofano A, Testa J . Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005; 94:29-86. DOI: 10.1016/S0065-230X(05)94002-5. View

Hoischen A, Ehrler M, Fassunke J, Simon M, Baudis M, Landwehr C . Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol. 2008; 18(3):326-37. PMC: 8095656. DOI: 10.1111/j.1750-3639.2008.00122.x. View

Blumcke I, Wiestler O . Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol. 2002; 61(7):575-84. DOI: 10.1093/jnen/61.7.575. View

Derouiche A, Frotscher M . Peripheral astrocyte processes: monitoring by selective immunostaining for the actin-binding ERM proteins. Glia. 2001; 36(3):330-41. DOI: 10.1002/glia.1120. View

Schick V, Majores M, Koch A, Elger C, Schramm J, Urbach H . Alterations of phosphatidylinositol 3-kinase pathway components in epilepsy-associated glioneuronal lesions. Epilepsia. 2007; 48 Suppl 5:65-73. DOI: 10.1111/j.1528-1167.2007.01291.x. View

Blumcke I, Lobach M, Wolf H, Wiestler O . Evidence for developmental precursor lesions in epilepsy-associated glioneuronal tumors. Microsc Res Tech. 1999; 46(1):53-8. DOI: 10.1002/(SICI)1097-0029(19990701)46:1<53::AID-JEMT5>3.0.CO;2-0. View

Pullen N, Thomas G . The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997; 410(1):78-82. DOI: 10.1016/s0014-5793(97)00323-2. View

Pagliusi S, Schachner M, Seeburg P, Shivers B . The Adhesion Molecule on Glia (AMOG) Is Widely Expressed by Astrocytes in Developing and Adult Mouse Brain. Eur J Neurosci. 1990; 2(5):471-480. DOI: 10.1111/j.1460-9568.1990.tb00438.x. View

10.

Baybis M, Yu J, Lee A, Golden J, Weiner H, McKhann 2nd G . mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol. 2004; 56(4):478-87. DOI: 10.1002/ana.20211. View

11.

Deb P, Sharma M, Tripathi M, Chandra P, Gupta A, Sarkar C . Expression of CD34 as a novel marker for glioneuronal lesions associated with chronic intractable epilepsy. Neuropathol Appl Neurobiol. 2006; 32(5):461-8. DOI: 10.1111/j.1365-2990.2006.00734.x. View

12.

Barkovich A, Kuzniecky R, Jackson G, Guerrini R, Dobyns W . A developmental and genetic classification for malformations of cortical development. Neurology. 2005; 65(12):1873-87. DOI: 10.1212/01.wnl.0000183747.05269.2d. View

13.

Majores M, Schick V, Engels G, Fassunke J, Elger C, Schramm J . Mutational and immunohistochemical analysis of ezrin-, radixin-, moesin (ERM) molecules in epilepsy-associated glioneuronal lesions. Acta Neuropathol. 2005; 110(6):537-46. DOI: 10.1007/s00401-005-1088-3. View

14.

Kwiatkowski D, Manning B . Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet. 2005; 14 Spec No. 2:R251-8. DOI: 10.1093/hmg/ddi260. View

15.

Mizuguchi M, Takashima S, Yamanouchi H, Nakazato Y, Mitani H, Hino O . Novel cerebral lesions in the Eker rat model of tuberous sclerosis: cortical tuber and anaplastic ganglioglioma. J Neuropathol Exp Neurol. 2000; 59(3):188-96. DOI: 10.1093/jnen/59.3.188. View

16.

Astrinidis A, Henske E . Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005; 24(50):7475-81. DOI: 10.1038/sj.onc.1209090. View

17.

Samadani U, Judkins A, Akpalu A, Aronica E, Crino P . Differential cellular gene expression in ganglioglioma. Epilepsia. 2007; 48(4):646-53. DOI: 10.1111/j.1528-1167.2007.00925.x. View

18.

Ferrier C, Aronica E, Leijten F, Spliet W, van Huffelen A, van Rijen P . Electrocorticographic discharge patterns in glioneuronal tumors and focal cortical dysplasia. Epilepsia. 2006; 47(9):1477-86. DOI: 10.1111/j.1528-1167.2006.00619.x. View

19.

Johnson M, Miyata H, Vinters H . Ezrin and moesin expression within the developing human cerebrum and tuberous sclerosis-associated cortical tubers. Acta Neuropathol. 2002; 104(2):188-96. DOI: 10.1007/s00401-002-0540-x. View

20.

Mak B, Kenerson H, Aicher L, Barnes E, Yeung R . Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol. 2005; 167(1):107-16. PMC: 1603434. DOI: 10.1016/s0002-9440(10)62958-6. View